Baseline characteristics stratified by BMI group
| Variable . | Normal weight . | Overweight . | Obese . | P value . |
|---|---|---|---|---|
| BMI < 25 kg/m2 . | BMI, 25-29.9 kg/m2 . | BMI ≥ 30 kg/m2 . | ||
| N = 49 . | N = 44 . | N = 41 . | ||
| BMI (kg/m2) | ||||
| Median [min-max] | 22.7 [17.9-24.9] | 27.3 [25.0-29.9] | 34.9 [30.2-55.2] | – |
| Age at CAR T-cell therapy (y) | ||||
| Median [min, max] | 68 [50-78] | 68 [39-85] | 65 [46-83] | .203 |
| Sex | ||||
| Male | 17 (34.7%) | 30 (68.2%) | 29 (70.7%) | <.001 |
| Race | ||||
| White | 39 (79.6%) | 34 (77.3%) | 36 (87.8%) | .510 |
| Black | 3 (6.1%) | 4 (9.1%) | 2 (4.9%) | |
| Asian | 5 (10.2%) | 1 (2.3%) | 1 (2.4%) | |
| Hispanic/Latino | 2 (4.1%) | 4 (9.1%) | 1 (2.4%) | |
| Other | 0 (0%) | 1 (2.3%) | 1 (2.4%) | |
| Lines of therapy prior to | ||||
| CAR T-cell therapy | ||||
| Median [min-max] | 4 [1-10] | 5 [1-16] | 4 [1-11] | .135 |
| MM subtype | ||||
| IgG kappa | 19 (38.8%) | 14 (31.8%) | 11 (26.8%) | .972 |
| IgG lambda | 8 (16.3%) | 7 (15.9%) | 8 (19.5%) | |
| IgA kappa | 5 (10.2%) | 5 (11.4%) | 4 (9.8%) | |
| IgA lambda | 2 (4.1%) | 5 (11.4%) | 4 (9.8%) | |
| Kappa light chain | 8 (16.3%) | 6 (13.6%) | 6 (14.6%) | |
| Lambda light chain | 7 (14.3%) | 7 (15.9%) | 7 (17.1%) | |
| Nonsecretory | 0 (0%) | 0 (0%) | 1 (2.4%) | |
| Extramedullary disease at CAR T-cell therapy | ||||
| Yes | 24 (49.0%) | 27 (61.4%) | 19 (46.3%) | .546 |
| No | 17 (34.7%) | 10 (22.7%) | 16 (39.0%) | |
| Unknown | 8 (16.3%) | 7 (15.9%) | 6 (14.6%) | |
| High-risk cytogenetics | ||||
| Yes | 17 (34.7%) | 21 (47.7%) | 13 (31.7%) | .181 |
| No | 30 (61.2%) | 19 (43.2%) | 26 (63.4%) | |
| Not available | 2 (4.1%) | 4 (9.1%) | 2 (4.9%) | |
| Prior AHCT | ||||
| Yes | 19 (38.8%) | 32 (72.7%) | 20 (48.8%) | .003 |
| ECOG performance status at CAR T-cell therapy | ||||
| 0 | 20 (40.8%) | 17 (38.6%) | 8 (19.5%) | .190 |
| 1 | 24 (49.0%) | 24 (54.5%) | 29 (70.7%) | |
| ≥2 | 5 (10.2%) | 3 (6.8%) | 4 (9.8%) | |
| Hypertension | ||||
| Yes | 27 (55.1%) | 25 (56.8%) | 30 (73.2%) | .177 |
| Hyperlipidemia | ||||
| Yes | 18 (36.7%) | 18 (40.9%) | 22 (53.7%) | .253 |
| Diabetes mellitus | ||||
| Yes | 3 (6.1%) | 6 (13.6%) | 11 (26.8%) | .024 |
| Anti-BCMA CAR T-cell construct | ||||
| Idecabtagene vicleucel | 20 (40.8%) | 28 (63.6%) | 21 (51.2%) | .266 |
| Ciltacabtagene autoleucel | 14 (28.6%) | 7 (15.9%) | 11 (26.8%) | |
| Investigational | 15 (30.6%) | 9 (20.5%) | 9 (22.0%) | |
| Time from apheresis to CAR T-cell infusion (d) | ||||
| Median [min-max] | 42 [29-82] | 40 [21-74] | 41 [30-92] | .231 |
| Bridging therapy prior to CAR T-cell therapy | ||||
| Yes | 37 (75.5%) | 32 (72.7%) | 30 (73.2%) | .939 |
| White blood cells (×109/L)∗ | ||||
| Median [min-max] | 3.86 [1.32-20.0] | 3.21 [1.79-6.78] | 3.91 [1.50-12.1] | .007 |
| Neutrophils (×109/L)∗ | ||||
| Median [min-max] | 2.47 [0.89-16.80] | 1.92 [0.59-5.95] | 2.71 [0.80-9.82] | .016 |
| Hemoglobin (g/dL)∗ | ||||
| Median [min-max] | 9.8 [5.7-12.4] | 10.0 [7.4-14.8] | 10.6 [7.0-14.8] | .108 |
| Platelets (×109/L)∗ | ||||
| Median [min-max] | 160 [9-381] | 113 [4-286] | 146 [20-387] | .040 |
| Ferritin (ng/mL)∗ | ||||
| Median [min-max] | 200 [14-4700] | 376 [20-8420] | 266 [12-4460] | .445 |
| CRP (mg/L)∗ | ||||
| Median [min-max] | 3.2 [0.2-127] | 5.0 [0.2-841] | 7.4 [0.7-289] | .067 |
| LDH (U/L)∗ | ||||
| Median [min-max] | 189 [122-879] | 184 [93-648] | 186 [111-1700] | .523 |
| Variable . | Normal weight . | Overweight . | Obese . | P value . |
|---|---|---|---|---|
| BMI < 25 kg/m2 . | BMI, 25-29.9 kg/m2 . | BMI ≥ 30 kg/m2 . | ||
| N = 49 . | N = 44 . | N = 41 . | ||
| BMI (kg/m2) | ||||
| Median [min-max] | 22.7 [17.9-24.9] | 27.3 [25.0-29.9] | 34.9 [30.2-55.2] | – |
| Age at CAR T-cell therapy (y) | ||||
| Median [min, max] | 68 [50-78] | 68 [39-85] | 65 [46-83] | .203 |
| Sex | ||||
| Male | 17 (34.7%) | 30 (68.2%) | 29 (70.7%) | <.001 |
| Race | ||||
| White | 39 (79.6%) | 34 (77.3%) | 36 (87.8%) | .510 |
| Black | 3 (6.1%) | 4 (9.1%) | 2 (4.9%) | |
| Asian | 5 (10.2%) | 1 (2.3%) | 1 (2.4%) | |
| Hispanic/Latino | 2 (4.1%) | 4 (9.1%) | 1 (2.4%) | |
| Other | 0 (0%) | 1 (2.3%) | 1 (2.4%) | |
| Lines of therapy prior to | ||||
| CAR T-cell therapy | ||||
| Median [min-max] | 4 [1-10] | 5 [1-16] | 4 [1-11] | .135 |
| MM subtype | ||||
| IgG kappa | 19 (38.8%) | 14 (31.8%) | 11 (26.8%) | .972 |
| IgG lambda | 8 (16.3%) | 7 (15.9%) | 8 (19.5%) | |
| IgA kappa | 5 (10.2%) | 5 (11.4%) | 4 (9.8%) | |
| IgA lambda | 2 (4.1%) | 5 (11.4%) | 4 (9.8%) | |
| Kappa light chain | 8 (16.3%) | 6 (13.6%) | 6 (14.6%) | |
| Lambda light chain | 7 (14.3%) | 7 (15.9%) | 7 (17.1%) | |
| Nonsecretory | 0 (0%) | 0 (0%) | 1 (2.4%) | |
| Extramedullary disease at CAR T-cell therapy | ||||
| Yes | 24 (49.0%) | 27 (61.4%) | 19 (46.3%) | .546 |
| No | 17 (34.7%) | 10 (22.7%) | 16 (39.0%) | |
| Unknown | 8 (16.3%) | 7 (15.9%) | 6 (14.6%) | |
| High-risk cytogenetics | ||||
| Yes | 17 (34.7%) | 21 (47.7%) | 13 (31.7%) | .181 |
| No | 30 (61.2%) | 19 (43.2%) | 26 (63.4%) | |
| Not available | 2 (4.1%) | 4 (9.1%) | 2 (4.9%) | |
| Prior AHCT | ||||
| Yes | 19 (38.8%) | 32 (72.7%) | 20 (48.8%) | .003 |
| ECOG performance status at CAR T-cell therapy | ||||
| 0 | 20 (40.8%) | 17 (38.6%) | 8 (19.5%) | .190 |
| 1 | 24 (49.0%) | 24 (54.5%) | 29 (70.7%) | |
| ≥2 | 5 (10.2%) | 3 (6.8%) | 4 (9.8%) | |
| Hypertension | ||||
| Yes | 27 (55.1%) | 25 (56.8%) | 30 (73.2%) | .177 |
| Hyperlipidemia | ||||
| Yes | 18 (36.7%) | 18 (40.9%) | 22 (53.7%) | .253 |
| Diabetes mellitus | ||||
| Yes | 3 (6.1%) | 6 (13.6%) | 11 (26.8%) | .024 |
| Anti-BCMA CAR T-cell construct | ||||
| Idecabtagene vicleucel | 20 (40.8%) | 28 (63.6%) | 21 (51.2%) | .266 |
| Ciltacabtagene autoleucel | 14 (28.6%) | 7 (15.9%) | 11 (26.8%) | |
| Investigational | 15 (30.6%) | 9 (20.5%) | 9 (22.0%) | |
| Time from apheresis to CAR T-cell infusion (d) | ||||
| Median [min-max] | 42 [29-82] | 40 [21-74] | 41 [30-92] | .231 |
| Bridging therapy prior to CAR T-cell therapy | ||||
| Yes | 37 (75.5%) | 32 (72.7%) | 30 (73.2%) | .939 |
| White blood cells (×109/L)∗ | ||||
| Median [min-max] | 3.86 [1.32-20.0] | 3.21 [1.79-6.78] | 3.91 [1.50-12.1] | .007 |
| Neutrophils (×109/L)∗ | ||||
| Median [min-max] | 2.47 [0.89-16.80] | 1.92 [0.59-5.95] | 2.71 [0.80-9.82] | .016 |
| Hemoglobin (g/dL)∗ | ||||
| Median [min-max] | 9.8 [5.7-12.4] | 10.0 [7.4-14.8] | 10.6 [7.0-14.8] | .108 |
| Platelets (×109/L)∗ | ||||
| Median [min-max] | 160 [9-381] | 113 [4-286] | 146 [20-387] | .040 |
| Ferritin (ng/mL)∗ | ||||
| Median [min-max] | 200 [14-4700] | 376 [20-8420] | 266 [12-4460] | .445 |
| CRP (mg/L)∗ | ||||
| Median [min-max] | 3.2 [0.2-127] | 5.0 [0.2-841] | 7.4 [0.7-289] | .067 |
| LDH (U/L)∗ | ||||
| Median [min-max] | 189 [122-879] | 184 [93-648] | 186 [111-1700] | .523 |
ECOG, Eastern Cooperative Oncology Group; Ig, immunoglobulin; LDH, lactate dehydrogenase; Max, maximum; Min, minimum.
On start date of LD.